Efficacy and safety analysis of lorlatinib for ALK-positive advanced NSCLC: a multicentre real-world study in China
Abstract Background Lorlatinib, a third-generation Anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (TKI), has demonstrated excellent curative effect in clinical studies to overcome mutations resistant to first- and second-generation ALK-TKIs. It also has improved blood-brain barrier cros...
Na minha lista:
| Principais autores: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMC
2025-07-01
|
| coleção: | BMC Cancer |
| Assuntos: | |
| Acesso em linha: | https://doi.org/10.1186/s12885-025-14631-w |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|